Onglyza

Onglyza is an oral drug for type 2 diabetes
Onglyza is an oral drug for type 2 diabetes

Onglyza (saxagliptin) is an oral prescription medicine for adults with type 2 diabetes.

Designed to be used alongside diet and exercise, the drug helps to control high blood glucose levels amongst type 2 diabetics.

How does Onglyza work?

Onglyza is a daily diabetes drug in the class known as gliptins (DPP-4 inhibitors).

These drugs help to control blood glucose levels by increasing the amount of insulin released by the pancreas and decreasing the body’s release of glucagon.

Onglyza is used alone or alongside other oral diabetes medicines.

These may include metformin, thiazolidinedione or a sulfonylurea.

Who is Onglyza made by?

Onglyza was brought to market by Bristol-Myers Squibb (BMS) and is marketed by BMS and AstraZeneca Pharmaceuticals LP.

Who shouldn’t take saxagliptin?

Saxagliptin should not be used by people with liver, kidney or heart problems and is not recommended for people over 75 years of age.

How effective is Onglyza?

Onglyza is an effective treatment for lowering blood glucose. As a result, patients should be aware that the drug may bring on episodes of low blood glucose levels (hypoglycemia).

What side effects have been reported with Onglyza?

The reported side effects of Onglyza include headaches, gastroenteritis, vomiting, respiratory tract infections and urinary tract infections. Hypoglycemia is a relatively common side effect.

I have type 2 diabetes, should I take Onglyza?

Your GP or healthcare professional will be able to tell you if you need to take Onglyza.